2025-07-08 - Analysis Report
Okay, here's an analysis of Eli Lilly and Co. (LLY) based on the data you provided, presented in English with simple figures and analysis:

**1. Performance Overview**

*   **Ticker:** LLY
*   **Company:** Eli Lilly and Co. (A global pharmaceutical company dedicated to creating medicines that make life better for people around the world.)

**Key Figures:**

*   **LLY Cumulative Return:** 251.35%
*   **S&P 500 (VOO) Cumulative Return:** 95.42%
*   **Absolute Deviation (LLY vs. VOO):** 156.4%
*   **Relative Deviation:** 54.2% (Relative to the historical range of deviation.)
*   **Current Price:** $780.67
*   **Previous Close:** $780.67
*   **Last Market Price:** $771.68
*   **Price Change:** -1.15
*   **5-Day Moving Average:** 778.64
*   **20-Day Moving Average:** 786.62
*   **60-Day Moving Average:** 777.37
*   **Market Risk Indicator (MRI):** 0.33 (Low Risk)
*   **RSI:** 37.98
*   **PPO:** -0.1484
*   **Expected Return:** 136.1% (Over S&P 500, long-term)

**Performance Analysis:**

*   **Outperformance:** LLY has significantly outperformed the S&P 500 (VOO) over the analyzed period. The cumulative return difference is substantial. The relative deviation of 54.2% indicates the current outperformance is above the historical median.
*   **Alpha/Beta:**
    The provided table shows a generally positive Alpha, indicating LLY's excess return relative to the market. Beta values are close to zero.

    | Year       | CAGR   | MDD    | Alpha   | Beta   | Cap(B)   |
    |------------|--------|--------|---------|--------|----------|
    | 2015-2017  | 10.0%  | 56.3%  | -19.0%  | 0.0    | 75.0     |
    | 2016-2018  | 39.0%  | 58.6%  | 21.0%   | -0.1   | 102.7    |
    | 2017-2019  | 50.0%  | 58.6%  | 20.0%   | 0.3    | 116.6    |
    | 2018-2020  | 52.0%  | 58.6%  | 33.0%   | 0.1    | 149.8    |
    | 2019-2021  | 106.0% | 60.6%  | 57.0%   | 0.2    | 245.1    |
    | 2020-2022  | 98.0%  | 64.8%  | 96.0%   | 0.2    | 324.6    |
    | 2021-2023  | 133.0% | 64.8%  | 115.0%  | 0.3    | 517.3    |
    | 2022-2024  | 150.0% | 72.2%  | 124.0%  | 0.2    | 685.1    |
    | 2023-2025  | 104.0% | 76.8%  | 57.0%   | 0.2    | 692.8    |

**2. Recent Price Action**

*   **Moving Averages:** The 5-day moving average is below the 20-day moving average, suggesting potential short-term downward momentum. The price ($780.67) being around the 60-day moving average indicates some consolidation.
*   **Last Market Price:** The last market price ($771.68) is below the previous close ($780.67) with a significant change of -1.15. This suggests a recent downward pressure.

**3. Technical Indicators**

*   **MRI:** The Market Risk Indicator (MRI) is at 0.33, indicating a low-risk environment.
*   **RSI:** An RSI of 37.98 suggests that the stock is approaching oversold conditions, which could signal a potential buying opportunity.
*   **PPO:** A PPO of -0.1484 indicates that the short-term moving average is slightly below the long-term moving average, confirming a downtrend.
*   **Hybrid Signal:** The hybrid signal recommends buying 80% of cash (3 shares), but with caution due to the MRI.
*   **Delta_Previous_Relative_Divergence:** The negative change in relative deviation (-3.3) confirms the short-term downward trend.
*   **Expected Return:** A high expected return of 136.1% indicates strong potential for long-term outperformance compared to the S&P 500.

**4. Recent News & Events**

*   **Business Developments & Regulatory Changes:** Eli Lilly has been in the news due to major business developments, regulatory changes, or market events.
*   **Analyst Discussions:** Analysts are actively discussing the company's recent performance and outlook.
*   **Stock Volatility:** The stock has shown notable volatility, influenced by recent news and earnings reports.
*   **Risk & Opportunities:** Market experts are highlighting both risks and opportunities for Eli Lilly.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-05-01 | 3.07 | 12.73 B$   |
| 2024-10-30 | 1.08 | 11.44 B$   |
| 2024-08-08 | 3.29 | 11.30 B$   |
| 2024-04-30 | 2.49 | 8.77 B$    |
| 2025-05-01 | 2.49 | 8.77 B$    |

*   **Earnings Trends:** The earnings per share (EPS) and revenue have shown an increasing trend over the recent quarters, suggesting strong financial performance.

**6. Financial Information**

Revenue and Profitability:

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-03-31 | $12.73B   | 82.53%        |
| 2024-12-31 | $13.53B   | 82.24%        |
| 2024-09-30 | $11.44B   | 81.02%        |
| 2024-06-30 | $11.30B   | 80.80%        |
| 2024-03-31 | $8.77B    | 80.91%        |

Capital and Profitability:

| Quarter    | Equity    | ROE       |
|------------|-----------|-----------|
| 2025-03-31 | $15.76B   | 17.50%    |
| 2024-12-31 | $14.19B   | 31.07%    |
| 2024-09-30 | $14.24B   | 6.81%     |
| 2024-06-30 | $13.56B   | 21.88%    |
| 2024-03-31 | $12.81B   | 17.51%    |

*   **Revenue and Profitability:** The company has shown consistent revenue growth with high-profit margins, indicating efficient operations.
*   **Capital and Profitability:** The Return on Equity (ROE) fluctuates, indicating variability in how efficiently the company generates profits from shareholders' equity.

**7. 종합적 분석 (Overall Analysis)**

*   **Positive Outlook:** Eli Lilly (LLY) demonstrates strong historical outperformance relative to the S&P 500 and maintains a positive long-term outlook with high expected returns.
*   **Recent Downtrend:** However, recent price action indicates a short-term downward trend with a negative change in relative deviation and prices falling below some key moving averages.
*   **Financial Strength:** Earnings, revenue, and profit margins are generally strong, supporting the company's growth.
*   **Considerations:** Investors should be aware of the stock's volatility and monitor recent news and company announcements. The hybrid signal suggests a cautious approach.
*   **Recommendation:** Considering the strong long-term potential, a gradual accumulation strategy might be appropriate, while closely monitoring short-term price action and market developments.
